tradingkey.logo

Treace Medical Concepts Inc reports results for the quarter ended December 31 - Earnings Summary

ReutersFeb 28, 2025 12:28 PM
  • Treace Medical Concepts Inc TMCI.OQ reported a quarterly adjusted loss of 1 cent​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -10 cents. The mean expectation of seven analysts for the quarter was for a loss of 4 cents per share. Wall Street expected results to range from -7 cents to -2 cents per share.

  • Revenue rose 10.4% to $68.71 million from a year ago; analysts expected $67.16 million.

  • Treace Medical Concepts Inc's reported EPS for the quarter was a loss of 1 cent​.

  • The company reported a quarterly loss of $501 thousand.

  • Treace Medical Concepts Inc shares had risen by 22.7% this quarter.

FORECAST CHANGES

  • The mean earnings estimate of analysts had fallen by about 5.2% in the last three months.​

  • In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "hold"

Wall Street's median 12-month price target for Treace Medical Concepts Inc is $9.50

This summary was machine generated from LSEG data February 28 at 12:28 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING

ESTIMATE

ACTUAL

BEAT, MET, MISSED

Dec. 31 2024

-0.04

-0.01

Beat

Sep. 30 2024

-0.27

-0.25

Beat

Jun. 30 2024

-0.29

-0.29

Met

Mar. 31 2024

-0.30

-0.30

Met

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI